These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26950189)

  • 1. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.
    Zuur MA; Bolhuis MS; Anthony R; den Hertog A; van der Laan T; Wilffert B; de Lange W; van Soolingen D; Alffenaar JW
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):509-21. PubMed ID: 26950189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
    Motta I; Calcagno A; Bonora S
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):59-82. PubMed ID: 29226732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dried blood spots: a new tool for tuberculosis treatment optimization.
    Vu DH; Alffenaar JW; Edelbroek PM; Brouwers JR; Uges DR
    Curr Pharm Des; 2011; 17(27):2931-9. PubMed ID: 21834763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis.
    Pranger AD; Kosterink JG; van Altena R; Aarnoutse RE; van der Werf TS; Uges DR; Alffenaar JW
    Ther Drug Monit; 2011 Jun; 33(3):350-4. PubMed ID: 21544017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
    Wasserman S; Meintjes G; Maartens G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):901-15. PubMed ID: 27532292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs and alternative possibilities in the treatment of tuberculosis.
    Hofman S; Segers MM; Ghimire S; Bolhuis MS; Sturkenboom MG; Van Soolingen D; Alffenaar JW
    Expert Opin Emerg Drugs; 2016; 21(1):103-16. PubMed ID: 26848966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The specific features of bacterial isolation and drug resistance of Mycobacteria in extrapulmonary tuberculosis].
    Vishnevskiĭ BI; Manicheva OA; Vishnevskaia EB; Mel'nikova NN; Otten TF
    Probl Tuberk Bolezn Legk; 2006; (11):18-21. PubMed ID: 17195585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing.
    Wilson ML
    Arch Pathol Lab Med; 2013 Jun; 137(6):812-9. PubMed ID: 23721277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular diagnosis of tuberculosis and drug resistance.
    Lin SY; Desmond EP
    Clin Lab Med; 2014 Jun; 34(2):297-314. PubMed ID: 24856529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance.
    Wilson ML
    Clin Infect Dis; 2011 Jun; 52(11):1350-5. PubMed ID: 21596676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs.
    Alffenaar JW
    J Infect Dis; 2012 Jun; 205(11):1765-6; author reply 1766. PubMed ID: 22459734
    [No Abstract]   [Full Text] [Related]  

  • 13. Tuberculosis drug resistance testing by molecular methods: opportunities and challenges in resource limited settings.
    Abebe G; Paasch F; Apers L; Rigouts L; Colebunders R
    J Microbiol Methods; 2011 Feb; 84(2):155-60. PubMed ID: 21129417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in rapid diagnosis of tuberculosis disease and anti-tuberculous drug resistance.
    Alcaide F; Coll P
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():34-40. PubMed ID: 21420565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis.
    Palomino JC
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):103-11. PubMed ID: 19416361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping.
    Springer B; Calligaris-Maibach RC; Ritter C; Böttger EC
    J Clin Microbiol; 2008 Dec; 46(12):4064-7. PubMed ID: 18923010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis.
    Salamon H; Yamaguchi KD; Cirillo DM; Miotto P; Schito M; Posey J; Starks AM; Niemann S; Alland D; Hanna D; Aviles E; Perkins MD; Dolinger DL
    J Infect Dis; 2015 Apr; 211 Suppl 2(Suppl 2):S50-7. PubMed ID: 25765106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The early bactericidal activity of anti-tuberculosis drugs: a literature review.
    Donald PR; Diacon AH
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S75-83. PubMed ID: 18762155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A family cluster of tuberculosis cases, including a case of acquired multidrug resistant tuberculosis.
    Holden J; Trachtman L
    J La State Med Soc; 2012; 164(1):43-7. PubMed ID: 22533114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.